|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
183,678,000 |
Market
Cap: |
4.53(B) |
Last
Volume: |
775,760 |
Avg
Vol: |
773,595 |
52
Week Range: |
$23.37 - $33.63 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Delivery |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 581 |
Guru Rank Value : 3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Alkermes is a biopharmaceutical company. Co. has a portfolio of marketed products focused on central nervous system disorders such as addiction and schizophrenia and a pipeline of product candidates in the fields of neuroscience and oncology. Co.'s proprietary products include: ARISTADA, which is an extended-release intramuscular injectable suspension approved in the U.S. for the treatment of schizophrenia; ARISTADA INITIO, which is indicated for the initiation of ARISTADA when used for the treatment of schizophrenia in adults; and VIVITROL, which is for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
35,000 |
Total Buy Value |
$0 |
$0 |
$0 |
$815,735 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
1 |
Total Shares Sold |
15,666 |
15,666 |
89,488 |
206,962 |
Total Sell Value |
$454,291 |
$454,291 |
$2,700,159 |
$6,056,962 |
Total People Sold |
3 |
3 |
4 |
6 |
Total Sell Transactions |
3 |
3 |
7 |
12 |
End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Pops Richard F |
Director and CEO, Alkermes plc |
|
2023-02-20 |
4 |
D |
$28.07 |
$1,491,780 |
D/D |
(53,145) |
1,034,867 |
|
- |
|
Pops Richard F |
Director and CEO, Alkermes plc |
|
2023-02-20 |
4 |
A |
$0.00 |
$0 |
D/D |
119,713 |
1,088,012 |
|
- |
|
Gaffin David Joseph |
EVP, CLO, Alkermes, Inc. |
|
2023-02-20 |
4 |
D |
$28.07 |
$185,739 |
D/D |
(6,617) |
117,938 |
|
- |
|
Gaffin David Joseph |
EVP, CLO, Alkermes, Inc. |
|
2023-02-20 |
4 |
A |
$0.00 |
$0 |
D/D |
15,468 |
122,486 |
|
- |
|
Gaffin David Joseph |
EVP, CLO, Alkermes, Inc. |
|
2023-02-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,036 |
109,087 |
|
- |
|
Brown Iain Michael |
SVP, Chief Financial Officer |
|
2023-02-20 |
4 |
D |
$28.07 |
$121,150 |
D/D |
(4,316) |
74,530 |
|
- |
|
Brown Iain Michael |
SVP, Chief Financial Officer |
|
2023-02-20 |
4 |
A |
$0.00 |
$0 |
D/D |
10,086 |
77,496 |
|
- |
|
Brown Iain Michael |
SVP, Chief Financial Officer |
|
2023-02-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,589 |
68,760 |
|
- |
|
Jackson Blair Curtis |
EVP, Chief Operating Officer |
|
2023-02-20 |
4 |
D |
$28.07 |
$121,150 |
D/D |
(4,316) |
104,313 |
|
- |
|
Jackson Blair Curtis |
EVP, Chief Operating Officer |
|
2023-02-20 |
4 |
A |
$0.00 |
$0 |
D/D |
10,086 |
107,279 |
|
- |
|
Jackson Blair Curtis |
EVP, Chief Operating Officer |
|
2023-02-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,589 |
98,543 |
|
- |
|
Nichols Christian Todd |
SVP, Chief Commercial Officer |
|
2023-02-18 |
4 |
D |
$28.07 |
$55,045 |
D/D |
(1,961) |
25,304 |
|
- |
|
Nichols Christian Todd |
SVP, Chief Commercial Officer |
|
2023-02-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,230 |
27,265 |
|
- |
|
Hopkinson Craig C. |
EVP R&D, Chief Medical Officer |
|
2023-02-18 |
4 |
D |
$28.07 |
$74,554 |
D/D |
(2,656) |
24,060 |
|
- |
|
Hopkinson Craig C. |
EVP R&D, Chief Medical Officer |
|
2023-02-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,722 |
26,716 |
|
- |
|
Landine Michael J |
SVP, Corp Dev., Alkermes, Inc. |
|
2023-02-18 |
4 |
D |
$28.07 |
$57,965 |
D/D |
(2,065) |
234,602 |
|
- |
|
Landine Michael J |
SVP, Corp Dev., Alkermes, Inc. |
|
2023-02-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,361 |
236,667 |
|
- |
|
Gaffin David Joseph |
EVP, CLO, Alkermes, Inc. |
|
2023-02-18 |
4 |
D |
$28.07 |
$54,596 |
D/D |
(1,945) |
102,051 |
|
- |
|
Gaffin David Joseph |
EVP, CLO, Alkermes, Inc. |
|
2023-02-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,230 |
103,996 |
|
- |
|
Brown Iain Michael |
SVP, Chief Financial Officer |
|
2023-02-18 |
4 |
D |
$28.07 |
$55,158 |
D/D |
(1,965) |
64,171 |
|
- |
|
Brown Iain Michael |
SVP, Chief Financial Officer |
|
2023-02-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,230 |
66,136 |
|
- |
|
Jackson Blair Curtis |
EVP, Chief Operating Officer |
|
2023-02-18 |
4 |
D |
$28.07 |
$75,312 |
D/D |
(2,683) |
93,954 |
|
- |
|
Jackson Blair Curtis |
EVP, Chief Operating Officer |
|
2023-02-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,722 |
96,637 |
|
- |
|
Daglio David Angelo Jr. |
Director |
|
2023-02-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,445 |
15,169 |
|
- |
|
Mckeon Brian P |
Director |
|
2023-02-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,445 |
15,169 |
|
- |
|
1496 Records found
|
|
Page 7 of 60 |
|
|